AI in Health and Medicine — Diagnosis, Research and Innovation
Basel, the world capital of the pharmaceutical industry, is at the heart of a medical revolution driven by artificial intelligence. From the laboratories of Roche and Novartis to Swiss university hospitals, AI is transforming every link in the healthcare chain — from early diagnosis to the discovery of new treatments.
AI-Assisted Diagnosis: Precision and Speed
Medical imaging is the field where AI has demonstrated its most spectacular results. Deep learning algorithms now outperform human radiologists in certain specific tasks:
Radiology and Imaging
- Breast cancer detection: AI systems reduce false negatives by 9.4% and false positives by 5.7% compared to radiologists alone
- Lung CT scan: detection of suspicious nodules with 97% sensitivity, crucial for early lung cancer screening
- Brain MRI: automated identification of tumours, strokes and neurodegenerative diseases
- Diabetic retinopathy: diagnosis through retinal imaging, deployable in regions without ophthalmologists
Digital Pathology
Digitised microscopy slides are analysed by neural networks capable of:
- Classifying cancerous tissues with accuracy comparable to senior pathologists
- Quantifying biomarkers in a standardised and reproducible manner
- Identifying patterns invisible to the human eye, paving the way for new prognostic markers
- Accelerating diagnosis from several days to just a few hours
The question of reliability and trust in these systems is paramount — a misdiagnosis can have life-threatening consequences.
Drug Discovery: From 10 Years to 2 Years
The traditional drug discovery process takes an average of 10 to 15 years and costs over 2 billion dollars. AI is drastically compressing these timelines:
Therapeutic Target Identification
AI algorithms analyse massive genomic, proteomic and metabolomic databases to identify new therapeutic targets. In Basel, Novartis uses AI to:
- Map biological pathways involved in diseases
- Predict protein-protein interactions through 3D modelling (inspired by AlphaFold)
- Identify responding patients for more targeted clinical trials
Molecule Design
Generative AI is revolutionising medicinal chemistry:
- De novo generation: creation of molecules optimised for a specific target
- Multi-objective optimisation: balancing efficacy, toxicity, bioavailability and synthesis
- ADMET prediction: anticipating pharmacokinetic behaviour before synthesis
- Drug repurposing: identification of new indications for existing drugs
Roche announced in 2025 that 40% of its research programmes now integrate AI at one stage or another of the discovery process.
Personalised Medicine and Genomics
The convergence of AI and genomics ushers in the era of precision medicine:
Genomic Sequencing and Interpretation
Interpreting a human genome (3 billion base pairs) is a colossal task. AI enables:
- Identifying pathogenic variants among the millions of detected variations
- Predicting polygenic risk for complex diseases (diabetes, cardiovascular diseases)
- Adapting treatments based on the patient's genetic profile (pharmacogenomics)
Precision Oncology
In oncology, AI analyses the molecular profile of each tumour to recommend the most suitable treatment. AI-assisted virtual tumour boards cross-reference:
- The tumour's genomic profile
- The patient's clinical data
- The global medical literature (over 30 million PubMed articles)
- Ongoing clinical trials
For Swiss medtech SMEs, these advances represent considerable commercial opportunities.
Conversational AI and Patient Monitoring
AI is not limited to laboratories. It is also transforming the patient-caregiver relationship:
Virtual Medical Assistants
Intelligent medical chatbots can:
- Triage symptoms and direct patients to the appropriate level of care
- Monitor chronic patients with personalised reminders
- Answer common health questions 24/7
- Detect signs of emergency and alert professionals
AI voice solutions play a growing role in this field, enabling elderly patients or those unfamiliar with technology to interact naturally with these systems.
Continuous Monitoring
Connected devices (watches, sensors) combined with AI enable continuous monitoring:
- Early detection of cardiac arrhythmias through continuous ECG
- Crisis prediction for epilepsy, asthma or diabetes
- Sleep analysis with personalised recommendations
- Mental health monitoring through behavioural pattern analysis
AI-Augmented Clinical Trials
Clinical trials, the longest and most expensive stage of pharmaceutical development, are being transformed by AI:
- Optimised recruitment: identification of eligible patients in electronic medical records
- Adaptive design: real-time modification of trial protocols based on interim results
- Side effect prediction: early detection of safety signals
- Digital twins: simulation of a treatment's effect on a virtual patient before actual administration
Ethical and Regulatory Challenges
AI in healthcare raises fundamental questions that intersect with ethics and trust in AI:
Health Data Protection
Medical data is among the most sensitive. In Switzerland, the revised FADP (Federal Act on Data Protection) and the European GDPR impose strict constraints:
- Robust anonymisation of patient data for model training
- Informed consent on the use of AI in the care pathway
- Right to explanation: the patient must be able to understand how an AI decision was made
- Data sovereignty: where are Swiss medical data stored and processed?
Medical Liability
Who is liable in the event of an AI diagnostic error? The physician, the hospital, the software developer? The legal framework is evolving, but grey areas persist.
Switzerland, a Leader in Digital Health
The Swiss ecosystem is particularly favourable to healthcare AI innovation, as shown by the AI panorama in Switzerland:
- Basel: the world pharmaceutical capital with Roche, Novartis and a dense biotech ecosystem
- Zurich: ETH Zurich at the forefront of medical AI research
- Lausanne: EPFL and its Human Brain Project
- Bern: Inselspital university hospital, a pioneer in AI-assisted robotic surgery
Conclusion
AI in medicine is not a distant promise — it is already a reality in Swiss and European hospitals and laboratories. From Basel to the entire continent, this silent revolution is saving lives, accelerating research and personalising care. Healthcare professionals who embrace this transformation will be best equipped to deliver medicine that is more precise, faster and more human.
Trust in these systems remains the key: medical AI is only useful if patients and caregivers trust it.
Further reading:
- Also read: AI in Germany 2025 — a pioneer in medical AI
- Discover our guide on generative AI architecture
- For a deeper dive, see AI and cybersecurity